Navigation Links
Kendle Reports Record 3Q 08 Net Income and Total Business Authorizations
Date:11/4/2008

ctive earnings, revenue and earnings growth, are forward-looking statements pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. All such forward-looking statements, including the statements contained herein regarding anticipated trends in the Company's business, are based largely on management's expectations and are subject to and qualified by risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. These risks and uncertainties include, without limitation, competitive factors and industry consolidation, outsourcing trends in the pharmaceutical and biotechnology industries, the Company's ability to manage growth and continue to attract and retain qualified personnel, the Company's ability to complete additional acquisitions and to integrate newly acquired businesses, the Company's ability to penetrate new markets, the fixed price nature of contracts and cost overruns, the loss, cancellation or delay of contracts or amendments thereto, the ability to maintain existing customer relationships or enter into new ones, the Company's sales cycle, the Company's ability to obtain financing on terms acceptable to the Company, the effects of exchange rate fluctuations, risks related to non-US operations and other factors described in the Company's filings with the Securities and Exchange Commission, including Quarterly Reports on Form 10-Q and the Annual Report on Form 10-K. No assurance can be given that the Company will be able to realize the net service revenues included in backlog and verbal awards. Kendle believes that its aggregate backlog and verbal awards are not necessarily a meaningful indicator of future results. All information in this release is current as of Nov. 4, 2008. The Company undertakes no duty to update any forward-looking statement to conform the statement to actual results or changes in the Company's expectations.


'/>"/>

SOURCE Kendle International Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. Kendle Named to FORTUNE List of 100 Fastest-Growing Companies for 2008
2. Kendle to Present at the UBS Global Life Sciences Conference
3. Kendle Invites You to Attend its Second Quarter 2008 Earnings Conference Call and Webcast
4. Kendle to Host Conference Call and Webcast to Discuss DecisionLine Acquisition and Provide Update on Second Quarter Progress
5. Kendle Expands Global Clinical Pharmacology Capabilities with Acquisition of DecisionLine Clinical Research Corporation
6. Kendle Appoints Patricia Williams Vice President, Commercial Operations
7. Kendle Invites You to Attend its First Quarter 2008 Earnings Conference Call and Webcast
8. Kendle to Present at the Lehman Brothers Eleventh Annual Global Healthcare Conference
9. Kendle Leaders Adopt 10b5-1 Trading Plans
10. Kendle to Present at the 29th Annual Raymond James Institutional Investors Conference
11. Kendle Hires Satish Tripathi, PhD, RAC as Vice President, Global Regulatory and Quality
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/14/2014)... Date: Friday, April 11, 2014 , Time: 6 p.m. ... Road, Warrington, Pa. , Details: The Hepatitis B ... a cure for hepatitis B and improving the quality of ... Ball on Friday, April 11 at Warrington Country Club in ...
(Date:1/14/2014)... CA (PRWEB) January 14, 2014 Histogen, ... the products of cells grown under simulated embryonic conditions, ... license agreement with Suneva Medical, Inc. for physician-dispensed aesthetic ... , This agreement is an amendment to ...
(Date:1/14/2014)... As pet owners drew up their lists of New Year,s ... better care of my furry companion." Nowadays there are pet salons, ... cases to take the little canine or feline darlings along wherever ... buy some pricey toys at the pet store. But anyone who ...
(Date:1/14/2014)... Jan. 14, 2014 The largest international professional ... plants and therapeutic derivatives thereof has endorsed an ... researchers about the challenges of adulterated herb and ... The Society for Medicinal Plant ...
Breaking Biology Technology:Hepatitis B Foundation to Host Annual Crystal Ball Gala 2Histogen and Suneva Medical Expand License for Cell Conditioned Media-based Aesthetic Products Internationally 2Histogen and Suneva Medical Expand License for Cell Conditioned Media-based Aesthetic Products Internationally 3New Year's Resolution: Give Pets the Gift of Top-Notch Health Care 2World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 2World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 3World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 4World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 5World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 6World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 7World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 8
... a Separate Study Also Show Minimal Effect on Heart Rhythm ... Changes in Schizophrenia Patients, ... psychopharmacologic agent being developed by Organon -- is effective,in treating acute ... III clinical studies, were presented this week at,the 20th European College ...
... provided a glimpse into how promising dielectric materials are ... performance of advanced electronic devices. This is revealed in ... Review Letters by researchers at the London Centre for ... Through the constant quest for miniaturization, transistors and all ...
... Medical,Inc. (Nasdaq: NXTM ), a leading manufacturer of ... for the third,quarter 2007 on Friday, November 2, 2007 ... also host a conference call at 10:00 a.m. Eastern ... 2007 financial results. To,listen to the conference call, please ...
Cached Biology Technology:Organon's Asenapine Further Demonstrates Efficacy in Reducing Mania Symptoms for the Treatment of Bipolar I Disorder 2Organon's Asenapine Further Demonstrates Efficacy in Reducing Mania Symptoms for the Treatment of Bipolar I Disorder 3Organon's Asenapine Further Demonstrates Efficacy in Reducing Mania Symptoms for the Treatment of Bipolar I Disorder 4Organon's Asenapine Further Demonstrates Efficacy in Reducing Mania Symptoms for the Treatment of Bipolar I Disorder 5Organon's Asenapine Further Demonstrates Efficacy in Reducing Mania Symptoms for the Treatment of Bipolar I Disorder 6Novel gate dielectric materials: perfection is not enough 2NxStage(R) Medical to Report Third Quarter 2007 Financial Results on Friday, November 2nd 2
(Date:4/17/2014)... of stem cell therapies to cure a variety of ... populations based on cell surface markers. Researchers from the ... is highly expressed in a type of stem cells ... in an article in BioResearch Open Access , ... The article is available free on the ...
(Date:4/17/2014)... A credit-card-sized anthrax detection cartridge developed at Sandia National ... testing safer, easier, faster and cheaper. , ... commonly found in soils all over the world and ... humans and animals. The bacteria can survive in harsh ... anthracis may occur through skin contact, inhalation of ...
(Date:4/17/2014)... marrow need to produce hydrogen sulfide in order to ... new study from the Center for Craniofacial Molecular Biology ... , Professor Songtao Shi, principal investigator on the project, ... cells governs the flow of calcium ions. The essential ... in osteogenesis, or the creation of new bone tissue, ...
Breaking Biology News(10 mins):Pocket-sized anthrax detector aids global agriculture 2Pocket-sized anthrax detector aids global agriculture 3
... dominant male and female to reduce their personal contribution to ... in Functional Ecology . , By removing the large ... cycle in this species a team from the University ... investment strategies of the dominant pair and the survival of ...
... Albert Einstein College of Medicine of Yeshiva ... as its twelfth Institutional Founding Member (IFM). A collaboration ... organizations, NYGC aims to transform medical research and clinical ... facilities in North America. "Einstein is pleased to ...
... directly lead to new ways of designing trials that would ... next few years and could change outcome for patients." ... 2013 will build on topics discussed in previous years and ... video here[ http://www.youtube.com/watch?v=X_anpC5WZPg ]: Breast cancer heterogeneity ...
Cached Biology News:Einstein joins the New York Genome Center as 12th institutional founding member 2IMPAKT -- Translational research breast cancer conference 2IMPAKT -- Translational research breast cancer conference 3
... Engineered with new technology incorporating the ... unsurpassed flexibility, the new Varian NMR ... spectrometer available today., ,The Varian NMR ... transmitter and receiver channel, providing pulse ...
... cell labeling mix, 92.5 MBq, ... stabilized with 0.1% 2-mercaptoethanol and ... acid. *Amino acid mixture for ... l-[35S]Methionine and l-[35S]Cysteine. * > ...
... MMP-3, Human, Assay, 96 wells. ELISA.Specific ... and complexed MMP-3. No cross-reactivity with MMP-1, ... ng/ml.Suitable for use with cell culture supernatant, ... at -15 to -30 C. Category: ...
... for serial preparation of ... including cytosol/particulate/cytoskeleton/nuclear fractions from ... fractions can directly be ... such as 2-D gel/Western ...
Biology Products: